Instrument Inactif

Autres langues Nektar Therapeutics Nasdaq

Actions

Recherche biotechnologique et médicale

Autres langues

30/09	Nektar Therapeutics Presents New Results From Multi-Omic Biomarker Sub-Study From REZOLVE-AD
30/09	Nektar Therapeutics Says Rezpegaldesleukin in Atopic Dermatitis Showed Improvements as Early as Week 2
30/09	New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
28/09	Nektar Therapeutics Announces Three Oral Presentations for Rezpegaldesleukin At the European Academy of Dermatology & Venereology Congress 2026
28/09	Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
25/09	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25/09	Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
25/09	Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
25/09	Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly -- Update
25/09	Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
25/09	Nektar Gets $90 Million Jury Award in Breach Suit Vs Eli Lilly
21/09	Nektar Therapeutics(NasdaqCM:NKTR) added to S&P Biotechnology Select Industry Index
21/09	Nektar Therapeutics(NasdaqCM:NKTR) dropped from S&P Pharmaceuticals Select Industry Index
31/08	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
28/08	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25/08	Nektar Therapeutics Publishes Positive Phase 2B Rezolve-Ad 16-Week Induction Results of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis
25/08	Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
13/08	Nektar: Q2 Earnings Snapshot
13/08	Nektar Therapeutics Q2 Loss Narrows, Revenue Declines
13/08	Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss
13/08	Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Earnings Flash (NKTR) Nektar Therapeutics Reports Q2 Revenue $10.1M, vs. FactSet Est of $10.4M
13/08	Nektar Therapeutics Announces Second Quarter 2026 Financial Results
29/07	Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
24/07	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)